170 related articles for article (PubMed ID: 15452549)
1. Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo.
Clarke PA; Pestell KE; Di Stefano F; Workman P; Walton MI
Br J Cancer; 2004 Oct; 91(8):1614-23. PubMed ID: 15452549
[TBL] [Abstract][Full Text] [Related]
2. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
3. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.
Pratesi G; Perego P; Polizzi D; Righetti SC; Supino R; Caserini C; Manzotti C; Giuliani FC; Pezzoni G; Tognella S; Spinelli S; Farrell N; Zunino F
Br J Cancer; 1999 Aug; 80(12):1912-9. PubMed ID: 10471039
[TBL] [Abstract][Full Text] [Related]
4. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
5. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
6. Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice.
Kolberg HC; Villena-Heinsen C; Deml MM; Kraemer S; Diedrich K; Friedrich M
Eur J Gynaecol Oncol; 2005; 26(4):398-402. PubMed ID: 16122187
[TBL] [Abstract][Full Text] [Related]
7. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
8. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
9. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission.
Farrand L; Byun S; Kim JY; Im-Aram A; Lee J; Lim S; Lee KW; Suh JY; Lee HJ; Tsang BK
J Biol Chem; 2013 Aug; 288(33):23740-50. PubMed ID: 23833193
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
[TBL] [Abstract][Full Text] [Related]
12. Aberrant p53 alters DNA damage checkpoints in response to cisplatin: downregulation of CDK expression and activity.
Wrighton KH; Prêle CM; Sunters A; Yeudall WA
Int J Cancer; 2004 Dec; 112(5):760-70. PubMed ID: 15386387
[TBL] [Abstract][Full Text] [Related]
13. Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene.
Yoshida Y; Hosokawa K; Dantes A; Tajima K; Kotsuji F; Amsterdam A
Int J Oncol; 2000 Aug; 17(2):227-35. PubMed ID: 10891529
[TBL] [Abstract][Full Text] [Related]
14. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI
Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
Abedini MR; Muller EJ; Brun J; Bergeron R; Gray DA; Tsang BK
Cancer Res; 2008 Jun; 68(12):4511-7. PubMed ID: 18559494
[TBL] [Abstract][Full Text] [Related]
16. The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment.
Dart DA; Picksley SM; Cooper PA; Double JA; Bibby MC
Int J Oncol; 2004 Jan; 24(1):115-25. PubMed ID: 14654948
[TBL] [Abstract][Full Text] [Related]
17. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.
Ning Y; Hui N; Qing B; Zhuo Y; Sun W; Du Y; Liu S; Liu K; Zhou J
Cell Death Dis; 2019 May; 10(6):414. PubMed ID: 31138778
[TBL] [Abstract][Full Text] [Related]
18. Tumoricidal activity of combining the agonistic DR5 antibody D-6 with cisplatin in C30 cisplatin-resistant ovarian cancer in vitro and in vivo.
Huang Y; Liang B; Jiang Q; Chen C; Yang K; Li C; Zheng A
Mol Med Rep; 2014 Jul; 10(1):183-90. PubMed ID: 24789319
[TBL] [Abstract][Full Text] [Related]
19. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
Bar JK; Harłozińska A; Popiela A; Noga L
Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]